Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers

• Verfasst von: Xia, Zhouchunyang [VerfasserIn]
• Verfasst von: Kommoss, Felix [VerfasserIn]
• Titel: Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers
• Verf.angabe: Zhouchunyang Xia MSc, Dawn R. Cochrane PhD, Basile Tessier-Cloutier MD, Samuel Leung MSc, Anthony N. Karnezis MD, PhD, Angela S. Cheng BSc, David A. Farnell MD, Jamie Magrill BS, Dietmar Schmidt MD, Stefan Kommoss MD, Felix K.F. Kommoss MD, Friederich Kommoss MD, Jessica N. McAlpine MD, C. Blake Gilks MD, Martin Koebel MD, Joseph T. Rabban MD, MPH, David G. Huntsman MD
• E-Jahr: 2019
• Jahr: 18 June 2019
• Umfang: 9 S.
• Teil: volume:92
• Teil: year:2019
• Teil: pages:39-47
• Teil: extent:9
• Fussnoten: Gesehen am 16.01.2020
• Titel Quelle: Enthalten in: Human pathology
• Ort Quelle: New York, NY [u.a.] : Elsevier, 1970
• Jahr Quelle: 2019
• Band/Heft Quelle: 92(2019), Seite 39-47
• ISSN Quelle: 1532-8392
• DOI: doi:10.1016/j.humpath.2019.06.001
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Gynecological cancers
• Sach-SW: L1ORF1p
• Sach-SW: LINE-1 retrotransposon
• Sach-SW: p53
• Sach-SW: Serous tubal intraepithelial carcinomas (STICs)
• K10plus-PPN: 1687534225

Abstract

LINE-1 (L1) retrotransposons are mobile genetic elements capable of “copy-and-pasting” their own sequences into random genomic loci, and one of the proteins it uses to achieve mobility is LINE-1 open reading frame 1 protein (L1ORF1p). L1ORF1p expression is found across many epithelial cancers, including small cohorts of ovarian and endometrial cancers, and is highly expressed in cancers with mutant p53 expressions. Here we aimed to gain insights into L1ORF1p expression levels within specific histotypes of ovarian cancers: high-grade serous (n=585), low-grade serous (n=26), clear cell (n=132), endometrioid (n=148), and mucinous (n=32) ovarian cancers, as well as endometrial cancers (n=607) using tissue microarray (TMA's). We demonstrated that L1ORF1p expression is associated with advanced stage and serous histotype in gynecological cancers. Like previous studies, we found a higher proportion of L1ORF1p expression in cases with aberrant p53 expression. We evaluated the expression of L1ORF1p in serous tubal intraepithelial carcinomas (STICs) (n=6) and p53 signature lesions (n=2) in fallopian tubes. Three STIC cases displayed aberrant p53 overexpression with corresponding L1ORF1p expression in the same tissues, but such correlation was not seen in the two p53 signature lesions, suggesting that L1 protein may be expressed after dysplastic transformation. The remaining three STIC cases have TP53 nonsense mutations with absent p53 expression but a strong and clear L1ORF1p expression within the STIC lesions. While L1ORF1p may not be prognostic in gynecological cancers, it may be useful clinically as a diagnostic IHC marker for p53 null STIC lesions and this warrants further investigation.